PATENT CLAIM ANALYSIS

Application Number: 16047499
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "093200"]

Abstract:
The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.

Claim (Index 9):
The recombinant HSV of  claim 1 , further comprising at least one additional miR target sequence incorporated into the ICP27 locus, wherein the additional miR target sequence is a sequence other than a miR-124 or a miR-122 target sequence.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 95.0
- Lexical Diversity: 1.42857
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13735760', '11855792', '15606747', '14112684', '11273640']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6624385732585579
- 35 USC 102 Novelty (BERT): 0.5403947816406587
- Combined Prediction Score: 0.650234194096768
- Mean Citation Score: 385.257516
- Max Citation Score: 388.0018
- Similarity Product: 243.0071374030113

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test